Statement from Sung Poblete, PhD, RN, CEO of FARE on the approval of needle-free intranasal epinephrine delivery device, neffy

"We commend the FDA's decision to approve ARS’s neffy, which offers the food allergy community a nasal-spray epinephrine delivery device," said Sung Poblete, PhD, RN, CEO of FARE. "This needle-free breakthrough should make it easier for food allergy patients and those around them to administer epinephrine in the event of an anaphylactic reaction. Importantly, we believe that innovation of this nature should also make it easier to have epinephrine more broadly available for use in the event of an emergency—in police cruisers, at restaurants, in airplanes, at hotels, at amusement parks and in other areas where accidental exposures are possible. This is a win for the food allergy community.”